Arcutis Biotherapeutics : FDA APPROVES ARCUTIS' ZORYVE™ (ROFLUMILAST) CREAM 0.3% FOR THE TREATMENT OF PLAQUE PSORIASIS IN INDIVIDUALS AGE 12 AND OLDER - Form 8-K

Press/Media

Period2 Aug 2022

Media coverage

1

Media coverage